High-density lipoproteins: Multifunctional vanguards of the cardiovascular system

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 3, 2004, Pages 417-430

  Marcil, Michel ^a   O'Connell, Brian ^a   Krimbou, Larbi ^a   Genest Jr , Jacques ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cardiovascular risk factors; Cholesterol; Epidemiology; Genetics; High density lipoprotein; Vascular endothelium

Indexed keywords

ABC TRANSPORTER; ANABOLIC AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN DERIVATIVE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PRAVASTATIN; PROBUCOL; PROSTACYCLIN; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG;

ADRENERGIC SYSTEM; APOPTOSIS; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; LIPOPROTEIN DEFICIENCY; MALE; PROTEIN TRANSPORT; PROTEOLIPOSOME; REVIEW; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; TANGIER DISEASE;

ANTILIPEMIC AGENTS; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; PROSTAGLANDINS; RECEPTORS, LIPOPROTEIN; VASOCONSTRICTION; VASODILATION;

EID: 2542445448     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.3.417     Document Type: Review

References (93)

1. Excecutive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults (Adult Treatment Panel III). J. Am. Med. Ass. 285, 2486-2497 (2001).
2. Assmann G, Nofer JR. Atheroproctective effects of high-density lipoproteins. Ann. Rev. Med. 54, 321-341 (2003).
3. Cockerill GW, Reed S. High-density lipoprotein: multipotent effects on cells of the vasculature. Int. Rev. Cytol. 188, 257-297 (1999).
4. O'Connell B, Genest J Jr. High-density lipoproteins and endothelial function. Circulation 104, 1978-1983 (2001).
5. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62, 707-714 (1977).
6. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124, S11-S20 (1996).
7. Despres J-P, Lemieux I, Dagenais G-R, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 153, 263-272 (2000).
8. Walsh J. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 281(5), 416-417 (2000).
9. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol. Circulation 86(4), 1165-1170 (1992).
10. Sacks FM, Tonkin AM, Shepherd J et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation, 102, 1893-1900 (2000).
11. Genest J Jr, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85, 2025-2033 (1992).
12. Genest J Jr, Bard J-M, Fruchart J-C, Ordovas JM, Schaefer EJ. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler. Thromb. 13, 1728-1737 (1993).
13. Marcil M, Bissonnette R, Vincent J, Krimbou L, Genest J. Cellular phospholipid and cholesterol efflux are major determinants of initial lipidation of high-density. Circulation 107, 1366-1371 (2003).
14. Von Eckardstein A, Nofer J-R, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21, 13-27 (2001).
15. Lund-Katz S, Liu L, Thuahnai T, Phillips MC. High-density lipoprotein structure. Front. Biosci. 8, d1044-d1054 (2003).
16. Acton S, Osgood D, Donoghue M et al. Association of polymorphisms at the SR-B1 gene locus with plasma lipid levels and body mass index in a white population. Arterioscler. Thromb. Vasc. Biol. 19, 1734-1743 (1999).
17. Fitzgerald ML, Morris AL, Rhee JS, Andersson LP, Mendez AJ, Freeman MW. Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J. Biol. Chem. 277(36), 33178-33187 (2002).
18. Babitt J, Trigatti B, Rigotti A et al. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J. Biol. Chem. 272(20), 13242-13249 (1997).
19. Gran GA, Connell PM, van der Westhuyzen DR, Smart EJ. The class B, Type I scavenger receptor promotes the selective uptake of high density cholesterol ethers into caveolae. J. Biol. Chem. 274, 12043-12048 (1999).
20. Denis M, Haidar B, Marcil M, Krimbou L, Genest J. Molecular and cellular physiology of apolipoprotein A-I lipidation by ATP biding cassette A1 (ABCA1). J. Biol. Chem. 279(9), 7384-7394(2003).
21. Denis M, Bissonnette R, O'Connell B et al. Expression, regulation and activity of ABCA1 in human cell lines. Mol. Genet. Metab. 78, 265-274 (2003).
22. Genest J. Lipoprotein disorders and cardiovascular risk. J. Inher. Metabol. Dis. 26, 267-287 (2003).
23. Calabresi L, Franceschini G. High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. Curr. Opin. Lipidol. 8(4), 219-224 (1997).
24. Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc. Med. 12(3), 121-128 (2002).
25. Perez-Mendez O, Bruckert E, Franceschini G et al. Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis 148(2), 317-325 (2000).
26. Frank PG, Marcel Y. Apolipoprotein A-I: structure-function relationship. J. Lipid Res. 41, 853-872 (2000).
27. Kuivenhoven JA, Pritchard H, Hill J et al. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J. Lipid Res. 38(2), 191-205 (1997).
28. Kondo I, Berg K, Drayna D, Lawn R. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels. Clin. Genet. 35(1), 49-56 (1989).
29. Kuivenhoven JA, de Knijff P, Boer JM et al. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 17(3), 560-568 (1997).
30. Yamashita S, Hirano K, Sakai N, Matsuzawa Y. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim. Biophys. Acta 1529(1-3), 257-725 (2000).
31. Inazu A, Jiang XC, Haraki T et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J. Clin. Invest. 1872-1882 (1994).
32. Feoli-Fonseca JC, Levy E, Godard M, Lambert M. Familial lipoprotein lipase deficiency in infancy: clinical, biochemical and molecular study. J. Pediat. 133(3), 417-423 (1998).
33. Ruel IL, Gauder D, Perron P, Bergeron J, Julien P, Lamarche B. Characterization of LDL particle size among carriers of a defective or a null mutation in the lipoprotein lipase gene: the Quebec LIPD Study. Arterioscler. Thromb. Vasc. Biol. 22(7), 1181-1186 (2002).
34. Fredrickson DS, Altrocchi PH, Avioli LV, Goodman DS, Goodman HC. Tangier disease. Ann. Intern. Med. 55, 1016-1031 (1961).
35. Marcil M, Yu L, Krimbou L et al. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency Arterioscler. Thromb. Vasc. Biol. 19(1),159-169 (1999).
36. Brooks-Wilson A, Marcil M, Clee S et al. Mutations in the ATP binding cassette (ABC1) transporter gene in Tangier disease and Familial HDL deficiency. Nat. Genet. 22, 336-345 (1999).
37. Bodzioch M, Orso E, Klucken J et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22, 347-351 (1999).
38. Rust S, Rosier M, Funke H et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22, 352-355 (1999).
39. Marcil M, Brooks-Wilson A, Clee S et al. Familial HDL Deficiency with defective cholesterol efflux is caused by mutations in cholesterol efflux regulatory protein (CERP/ABC1). Lancet 354, 1341-1346 (1999).
40. Clee SM, van Dam M, Marcil M et al. HDL levels and coronary artery disease in heterozygotes for ABCA1 mutations are predicted by cholesterol efflux levels and influenced by age. J. Clin. Invest. 106, 1263-1270 (2000).
41. Matsuda Y, Hirata K, Inoue N et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent relaxation. Circ. Res. 72, 1103-1109 (1993).
42. Blair A, Shaul PW, Yuhanna IS et al. Oxidized low density lipoprotein displaces endothelial nitric oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J. Biol. Chem. 274, 32512-32519 (1999).
43. Plane F, Bruckdorfer KR, Keff P et al. Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated by endothelium-derived nitric oxide in rabbit aorta. Br. J. Pharmacol. 105, 216-222 (1992).
44. Uittenbogaard A, Shaul PW, Yuhanna IS et al. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric oxide synthase localization and activation in caveolae. J. Biol. Chem. 275, 11278-11283 (2000).
45. Yuhana IS, Zhu Y, Cox BE et al. High-density lipoprotein binding to scavenger receptor B1 activated endothelial nitric oxide synthase. Nat. Med. 7, 853-857 (2001).
46. Cominacini L, Pasini AF, Garbin U et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J. Biol. Chem. 276(17), 13750-13755 (2001).
47. Schaefer EJ, Blum CB, Levy RI, Jenkins LL, Alaupovic P, Foster DM, Brewer HB Jr. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N. Engl. J Med. 299, 905-910 (1978).
48. Gong M, Wilson M, Kelly T et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J. Clin. Invest. 111, 1579-1587 (2003).
49. 2 synthetase activity by phospholipids (PL), cholesterol esters (CE), unesterified fatty acids (UFA) and lipoproteins (LDL and HDL). Artery 8, 494-500 (1980).
50. PomerantzKB, Fleisher LN, Tall AR et al. Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis. J. Lipid Res. 26, 1269-1276 (1985).
51. Oravec S, Demuth K, Myara I et al. The effect of high density lipoprotein subfractions on endothelial eicosanoid secretion. Thromb. Res. 92, 65-71 (1998).
52. Sugatani J, Miwa M, Komiyama Y et al. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J. Lipid Mediat. Cell Signal. 13, 73-88 (1996).
53. Kawaguchi A, Miyao Y, Noguchi T et al. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler. Thromb. Vasc. Biol. 20, 251-258 (2000).
54. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue-factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler. Thromb. 14, 223-229 (1994).
55. Cigolini M, Targher G, Seidell JC et al. Relationships of plasminogen activator inhibititor-1 to anthropometry, serum insulin, tryglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis 106, 139-147 (1994).
56. Zitoun D, Bara L, Basdevant A, Samama MM. Related articles, links levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler. Thromb. Vasc. Biol. 16(1), 77-81 (1996).
57. Griffin JH, Kojima K, Banka CI, Curtiss LK, Fernandez JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. 103(2), 219-227 (1999).
58. Cockerill GW, Rye K, Gamble JR et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15, 1987-1994 (1995).
59. Hwang SJ, Ballantyne CM et al. Circulating adhesion molecules VCAM- 1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96, 4219-4225 (1997).
60. Cockerill GW, Huehns TY, Weerasinghe A et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an invivo model of acute inflammation. Circulation 103, 108-112 (2001).
61. Baker PW, Rye K, Gamble JR et al. Ability of reconstituted high density lipoproteins to inhibit cymkine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothetial cells. J. Lipid Res. 40, 345-353 (1999).
62. Stannard AK, Khan S, Graham A, Owen JS, Allen SP. Inability of plasma high-density lipoproteins to inhibit cell adhesion molecule expression in human coronary artery endothelial cells. Atherosclerosis 154, 31-38 (2001).
63. Zhang WJ, Stocker R, McCall MR, Forte TM, Frei B. Lack of inhibitory effect of HDL on TNFα-induced adhesion molecule expression in human aortic endothelial cells. Atherosclerosis 165, 241-249 (2001).
64. Xia P, Vadas MA, Rye K et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. J. Biol. Chem. 274, 33143-33147 (1999).
65. Sugano M, Tsuchida K, Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-induced apoptosis. Biochem. Biophys. Res. Commun. 272, 872-876 (2000).
66. Nofer JR, Fobker M, Hobbel G et al. Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry 39, 15199-15207 (2000).
67. Kimura T, Sato K, Malchinkhuu E et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Atheroscler. Thromb. Vasc. Biol. 23, 1283-1288 (2003).
68. Honda HM, Wakamatsu BK, Goldhaber JI et al. High-density lipoprotein increases intracellular calcium levels by releasing calcium from internal stores in human endothelial cells. Atherosclerosis 149, 299-306 (1999).
69. Krimbou L, Marcil M, Davignon J, Genest J Jr. Interaction of lecithin: cholesterol acyltransferase (LCAT).alpha 2-macroglobulin complex with low density lipoprotein receptor-related protein (LRP). Evidence for an α2-macroglobulin/LRP receptor-mediated system participating in LCAT clearance. J. Biol. Chem. 276, 33241-33248 (2001).
70. Watson AD, Berliner JA, Hama SY et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96(6), 288-291 (1995).
71. Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med. 11, 155-161 (2001).
72. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl. Acad. Sci. USA 90(24), 12040-12044 (1993).
73. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp. Med. 180, 1025-1035 (1994).
74. Ansell BJ, Navab M, Hama S et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108, 2751-2756 (2003).
75. Genest J, Pedersen TR. Prevention of cardiovascular ischemic events: high-risk and secondary prevention. Circulation. 107, 2059-2065 (2003).
76. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 102, 21-27 (2000).
77. Rubins HB, Sander J, Robins SJ et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. N. Engl. J. Med. 341, 410-418 (1999).
78. Steiner G. On behalf of the DAIS Investigators. Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 357, 905-910 (2001).
79. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280(7), 605-613 (1998).
80. Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am. J. Cardiol. 88, 14N-18N (2001).
81. Martin G, Duez H, Blanquart C et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest. 107(11), 1423-1432 (2001).
82. Sikorski JA, Connolly DT. The discovery of new cholesteryl ester transfer protein inhibitors. Curr. Opin. Drug Discov. Devel. 4(5), 602-613 (2001).
83. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized Phase II dose-response study. Circulation 105(18), 2159-2165 (2002).
84. Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Atheroscler. Thromb. Vasc. Biol. 23, 1169-1177 (2003).
85. Covey SD, Krieger M, Wang W, Penman M, Trigatti BL. Scavenger receptor class B Type I-mediated protection against atherosclerosis in LDL-receptor-negative mice involves expression in bone-marrow-derived cells. Atheroscler. Thromb. Vasc. Biol. 23(9), 1589-1594 (2003).
86. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-B1 reduces atherosclerosis in the cholesterol-fed mouse. Atheroscler. Thromb. Vasc. Biol. 20, 721-727 (2000).
87. Acton S, Kozarsky KF, Rigotti A. The HDL receptor SR-B1: a new therapeutic target for atherosclerosis? Mol. Med. Today 5, 518-523 (1999).
88. Newton RS, Krause BR. HDL therapy for the acute treatment of atherosclerosis. Atherosclerosis 3(Suppl. 4), 31-38 (2002).
89. Bisoendial RJ, Hovingh K, Levels JHM et al. Restoration of endothelial function by increasing high density lipoproteins an subjects with isolated low high density lipoprotein. Circulation 107, 2944-2948 (2003).
90. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300 (2003).
91. Navab M, Anantharamaiah GM, Reddy ST et al. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Curr. Opin. Investig. Drug 4(9), 1100-1104 (2003).
92. Smith AB, Esko JD, Hajduk SL. Killing of trypanosomes by the human haptoglobin-related protein. Science 268, 284-286 (1995).
93. Raper J, Nussenzweig V, Tomlinson S. The main lytic factor of Trypanosoma brucei brucei in normal human serum is not high density lipoprotein. J. Exp. Med. 183, 1023-1029 (1996).